OrthoPediatrics Corp. - Common Stock (KIDS)

Disciplined capital spending on surgical sets is finally unlocking positive free cash flow, signaling that the company can scale without burning cash.

OrthoPediatrics (NASDAQ:KIDS) reported record third-quarter revenue and raised its full-year sales outlook, citing broad-based demand across its trauma, deformity, scoliosis and specialty bracing businesses, as well as continued progress from recently introduced products. Revenue for the third quar

Record Q3 revenue of $72.7 million driven by strong implant and specialty bracing demand.

OrthoPediatrics (NASDAQ:KIDS) reported record revenue, adjusted EBITDA and number of children helped during the second quarter, as the pediatric orthopedic device company began to see early contributions from its newer “super cycle” products, Chief Executive Officer Dave Bailey said at the Canaccord

Trauma and deformity revenue surged 26% as adjusted EBITDA hit record $6.8 million.

OrthoPediatrics (NASDAQ:KIDS) reported record second-quarter revenue of $70.5 million, up 15% from a year earlier, as strong Trauma & Deformity and specialty bracing performance offset a reported decline in scoliosis revenue. The company also raised its 2026 revenue outlook while maintaining its

OrthoPediatrics (KIDS) Q1 2026 Earnings Transcript

OrthoPediatrics (KIDS) Q4 2025 Earnings Transcript

OrthoPediatrics (KIDS) reported Q3 2025 results with strong revenue growth and a narrower-than-expected loss, driving a positive market reaction.